MX2020007941A - Metodo para prevenir o tratar enfermedad de alzheimer. - Google Patents

Metodo para prevenir o tratar enfermedad de alzheimer.

Info

Publication number
MX2020007941A
MX2020007941A MX2020007941A MX2020007941A MX2020007941A MX 2020007941 A MX2020007941 A MX 2020007941A MX 2020007941 A MX2020007941 A MX 2020007941A MX 2020007941 A MX2020007941 A MX 2020007941A MX 2020007941 A MX2020007941 A MX 2020007941A
Authority
MX
Mexico
Prior art keywords
disease
preventing
treating alzheimer
subject
dapansutrile
Prior art date
Application number
MX2020007941A
Other languages
English (en)
Inventor
Charles A Dinarello
Original Assignee
Olatec Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Therapeutics Llc filed Critical Olatec Therapeutics Llc
Publication of MX2020007941A publication Critical patent/MX2020007941A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige a un método para prevenir y/o tratar la enfermedad de Alzheimer. El método comprende administrar a un sujeto que lo necesite una cantidad efectiva de dapansutril. El método reduce la neuroinflamación y mejora las funciones cognitivas, como el aprendizaje y los procesos de memoria del sujeto. El dapansutril puede administrarse al sujeto por vía oral a una dosis de 100-2000 mg/día durante 3 meses a 5 años o más.
MX2020007941A 2018-01-31 2019-01-31 Metodo para prevenir o tratar enfermedad de alzheimer. MX2020007941A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862624637P 2018-01-31 2018-01-31
PCT/US2019/016012 WO2019152627A1 (en) 2018-01-31 2019-01-31 Method for preventing or treating alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2020007941A true MX2020007941A (es) 2020-09-03

Family

ID=67478566

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007941A MX2020007941A (es) 2018-01-31 2019-01-31 Metodo para prevenir o tratar enfermedad de alzheimer.

Country Status (7)

Country Link
US (1) US11517554B2 (es)
EP (1) EP3746057B1 (es)
JP (1) JP7290872B2 (es)
CN (1) CN111670032A (es)
CA (1) CA3087865A1 (es)
MX (1) MX2020007941A (es)
WO (1) WO2019152627A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3768384A4 (en) * 2018-03-21 2021-11-17 Olatec Therapeutics LLC METHOD OF TREATMENT OF MELANOMAS
AU2020366300A1 (en) * 2019-10-14 2022-06-02 Olatec Therapeutics Llc Methods for treating breast cancer
CN117897151A (zh) * 2021-08-19 2024-04-16 欧拉泰克治疗公司 用于治疗帕金森氏病的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013014583A2 (pt) * 2010-12-15 2016-09-20 Olatec Ind Llc composição farmacêutica, e, métodos para o tratamento de inflamação, para o tratamento da dor, e para preparar 3-metanossulfonilpropionitrila
AU2013334874B2 (en) * 2012-10-25 2018-04-05 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
JP2016520615A (ja) * 2013-05-31 2016-07-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法
WO2015165961A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
EP3261644B1 (en) * 2015-02-26 2021-06-02 University Of Kentucky Research Foundation Compositions and methods for treating retinal degradation

Also Published As

Publication number Publication date
US20200352897A1 (en) 2020-11-12
WO2019152627A1 (en) 2019-08-08
EP3746057A1 (en) 2020-12-09
JP2021512086A (ja) 2021-05-13
US11517554B2 (en) 2022-12-06
EP3746057A4 (en) 2021-10-13
EP3746057B1 (en) 2024-03-20
CN111670032A (zh) 2020-09-15
CA3087865A1 (en) 2019-08-08
JP7290872B2 (ja) 2023-06-14

Similar Documents

Publication Publication Date Title
MX2020007941A (es) Metodo para prevenir o tratar enfermedad de alzheimer.
MX2023001299A (es) Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos.
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
PH12021500006A1 (en) Methods of treatment and prevention of alzheimer's disease
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
PH12021550043A1 (en) Use of riluzole prodrugs to treat alzheimer's disease
MX2022010748A (es) Metodos para tratar la glomeruloesclerosis segmentaria focal dependiente de apolipoproteina l1 (apol-1).
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
FR3079141B1 (fr) Utilisations de derives de curcumine
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
MY193963A (en) Composition for treating joint diseases and kit containing same
EA202192928A1 (ru) Терапевтическое лекарственное средство для лечения дискинезии
Woo Recent updates on chemotherapy-induced peripheral neuropathy
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
MX2019002827A (es) Acidos grasos omega 3 y colina como neuroprotectores en pacientes sin demencia.
PH12020551470A1 (en) Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
PL425832A1 (pl) Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
EA202190406A1 (ru) Способы лечения нейродегенеративных расстройств
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага